<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization - Health AI Hub</title>
    <meta name="description" content="FRAGMENTA is an end-to-end framework designed for drug lead optimization, addressing the challenges of limited class-specific molecular data and inefficient mod">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.20510v1" target="_blank">2511.20510v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-25
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Yuto Suzuki, Paul Awolade, Daniel V. LaBarbera, Farnoush Banaei-Kashani
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.20510v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.20510v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">FRAGMENTA is an end-to-end framework designed for drug lead optimization, addressing the challenges of limited class-specific molecular data and inefficient model tuning. It integrates a novel generative model that uses dynamic Q-learning to jointly optimize molecular fragmentation and generation, with an agentic AI system for expert-driven objective refinement. This approach significantly improves the identification of high-scoring drug candidates, demonstrating superior performance in real-world cancer drug discovery experiments and advancing towards autonomous model tuning.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research significantly accelerates and enhances the efficiency of identifying promising drug candidates, particularly vital for diseases where data is scarce. By streamlining the initial phases of drug discovery, it holds the potential to reduce development timelines and costs for new therapeutics.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>FRAGMENTA applies generative AI and agentic systems to accelerate and optimize the drug discovery process. Specifically, it enables the generation of novel drug lead molecules by reframing fragmentation and using dynamic Q-learning. The agentic AI system facilitates autonomous tuning of models based on expert feedback, aiming to remove human AI engineers from the loop and progressively learn domain knowledge. This directly translates to faster and more efficient identification of potential drug candidates for various diseases, as demonstrated in cancer drug discovery experiments.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses critical limitations in drug discovery: scarcity of class-specific molecular training data (<100 examples) and slow, indirect human collaboration for model tuning.</li>
                    
                    <li>Introduces a novel generative model that reframes molecular fragmentation as a 'vocabulary selection' problem, moving beyond heuristic methods.</li>
                    
                    <li>Employs dynamic Q-learning to achieve joint optimization of both the fragmentation process and subsequent molecule generation.</li>
                    
                    <li>Incorporates an agentic AI system capable of refining optimization objectives through conversational feedback from domain experts (e.g., medicinal chemists).</li>
                    
                    <li>Aims to progressively learn domain knowledge, thereby automating the model tuning process and removing the AI engineer from the loop.</li>
                    
                    <li>In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules compared to baseline methods.</li>
                    
                    <li>The fully autonomous Agent-Agent system outperformed traditional Human-Human tuning, demonstrating the efficacy of agentic tuning in accurately capturing and applying expert intent.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>FRAGMENTA employs a two-component methodology: 1) A novel generative model that utilizes dynamic Q-learning to jointly optimize molecule fragmentation (viewed as vocabulary selection) and subsequent generation. 2) An agentic AI system designed to learn and refine optimization objectives through iterative, conversational feedback from human domain experts, with the goal of progressively automating the model tuning process.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>["FRAGMENTA's Human-Agent configuration achieved nearly double the number of high-scoring molecules compared to baseline methods in real-world cancer drug discovery experiments.", 'The fully autonomous Agent-Agent system demonstrated superior performance over traditional Human-Human tuning, proving the effectiveness of agentic tuning in capturing expert intent.', 'The framework successfully moved towards automating the model tuning process, thereby reducing the dependency on AI engineers and incorporating domain expertise more directly.']</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>By drastically improving the efficiency and accuracy of identifying high-scoring drug leads, FRAGMENTA can significantly shorten the preclinical phases of drug development. This could lead to a faster pipeline for novel therapeutics, particularly in challenging areas like cancer where patient needs are urgent, potentially bringing life-saving drugs to market more quickly and cost-effectively.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract primarily highlights the limitations of existing approaches that FRAGMENTA aims to overcome (e.g., heuristic fragmentation limiting diversity, slow human-AI collaboration for tuning). Specific intrinsic limitations or caveats of the FRAGMENTA framework itself are not explicitly detailed within the provided abstract, although the complexity of dynamic Q-learning and agentic feedback loops could imply computational demands or initial setup overheads.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The system is designed to progressively learn domain knowledge to eventually automate tuning, implying ongoing development towards more robust and fully autonomous drug lead optimization. Further research could explore its applicability across a broader range of disease areas and molecular design challenges, as well as refining the dynamic Q-learning mechanism.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">generative AI</span>
                    
                    <span class="tag tag-keyword">drug discovery</span>
                    
                    <span class="tag tag-keyword">molecule generation</span>
                    
                    <span class="tag tag-keyword">fragmentation</span>
                    
                    <span class="tag tag-keyword">Q-learning</span>
                    
                    <span class="tag tag-keyword">agentic AI</span>
                    
                    <span class="tag tag-keyword">lead optimization</span>
                    
                    <span class="tag tag-keyword">cancer therapeutics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Molecule generation using generative AI is vital for drug discovery, yet class-specific datasets often contain fewer than 100 training examples. While fragment-based models handle limited data better than atom-based approaches, existing heuristic fragmentation limits diversity and misses key fragments. Additionally, model tuning typically requires slow, indirect collaboration between medicinal chemists and AI engineers. We introduce FRAGMENTA, an end-to-end framework for drug lead optimization comprising: 1) a novel generative model that reframes fragmentation as a "vocabulary selection" problem, using dynamic Q-learning to jointly optimize fragmentation and generation; and 2) an agentic AI system that refines objectives via conversational feedback from domain experts. This system removes the AI engineer from the loop and progressively learns domain knowledge to eventually automate tuning. In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules as baselines. Furthermore, the fully autonomous Agent-Agent system outperformed traditional Human-Human tuning, demonstrating the efficacy of agentic tuning in capturing expert intent.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>